Volixibat
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2015 (NCT02287779)
Timeline
Indications
Mechanism of action
- Ileal bile acid transporterINHIBITOR
SLC10A2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCC[C@]1(CC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2cccc(NC(=O)N[C@@H]3O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](OCc4ccccc4)[C@H]3O)c2)[C@H]1O- Mol. weight
- 805.97 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3707222 ↗
Also known as
- shp626
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05050136 | Phase 2 | Sep 22, 2021 | Mirum Pharmaceuticals, Inc. |
| NCT04718961 | Phase 2 | Jan 4, 2021 | Mirum Pharmaceuticals, Inc. |
| NCT04663308 | Phase 2 | Dec 31, 2020 | Mirum Pharmaceuticals, Inc. |
| NCT02787304 | Phase 2 | Jul 1, 2016 | Shire |
| NCT02571192 | Phase 1 | Oct 1, 2015 | Covance, Shire |
| NCT02475317 | Phase 1 | Jun 1, 2015 | Shire |
| NCT02287779 | Phase 1 | Jan 1, 2015 | Shire |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shire | For profit | 4 | 4 | 2 | 2015 |
| Mirum Pharmaceuticals, Inc. | For profit | 3 | 3 | 1 | 2020 |
| Covance | For profit | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1